Christoph Suppan

555 total citations
32 papers, 241 citations indexed

About

Christoph Suppan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christoph Suppan has authored 32 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 19 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christoph Suppan's work include Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (13 papers) and Advanced Breast Cancer Therapies (11 papers). Christoph Suppan is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (13 papers) and Advanced Breast Cancer Therapies (11 papers). Christoph Suppan collaborates with scholars based in Austria, Germany and United States. Christoph Suppan's co-authors include Marija Balić, Nadia Dandachi, Florian Posch, Vesna Bjelic‐Radisic, Katharina Eberhard, Hans Loibner, Andrea Groselj‐Strele, Hellmut Samonigg, Herbert Stoeger and Ellen Heitzer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Christoph Suppan

26 papers receiving 239 citations

Peers

Christoph Suppan

ONCOL

PRM

PFM

Isabel Heidrich Germany

Laura Arthur United Kingdom

Mercedes Rodríguez-Garrote Spain

Saskia Hussung Switzerland

Hasan Mirza United Kingdom

Zhao-Li Tan China

Daniel C. Bruhm United States

Phuong Vu Norway

Wenbo Zheng China

Cecilia Anesi Italy

Isabel Heidrich Germany

Christoph Suppan

172 ×1.1

ONCOL

192 ×1.4

128 ×1.6

67 ×1.4

PRM

42 ×1.4

PFM

Citations per year, relative to Christoph Suppan Christoph Suppan (= 1×) peers Isabel Heidrich

Countries citing papers authored by Christoph Suppan

Since Specialization

Citations

This map shows the geographic impact of Christoph Suppan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Suppan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Suppan more than expected).

Fields of papers citing papers by Christoph Suppan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Suppan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Suppan. The network helps show where Christoph Suppan may publish in the future.

Co-authorship network of co-authors of Christoph Suppan

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Suppan. A scholar is included among the top collaborators of Christoph Suppan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Suppan. Christoph Suppan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bartsch, Rupert, Zsuzsanna Bagó-Horváth, Daniel Egle, et al.. (2025). New Perspectives in the Management of Triple-Negative Breast Cancer. Breast Care. 1–14.

Hlauschek, Dominik, Daniel Egle, Zsuzsanna Bagó-Horváth, et al.. (2025). Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.. Journal of Clinical Oncology. 43(16_suppl). 510–510.

Khaled, Najib Ben, Liangtao Ye, Ralf Wimmer, et al.. (2025). Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance. Cellular Oncology. 48(5). 1363–1375.

Wimmer, Kerstin, Dominik Hlauschek, Marija Balić, et al.. (2024). Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?. Breast Cancer Research and Treatment. 205(2). 227–239. 1 indexed citations

Gnant, Michael, Marija Balić, Gabriel Rinnerthaler, et al.. (2024). Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer. memo - Magazine of European Medical Oncology. 18(1). 4–18.

Suppan, Christoph. (2024). Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities. memo - Magazine of European Medical Oncology. 17(4). 251–253.

Hlauschek, Dominik, Georg Pfeiler, Daniel Egle, et al.. (2024). Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.. Journal of Clinical Oncology. 42(16_suppl). 587–587. 1 indexed citations

Brčić, Iva, Christoph Suppan, Peter Regitnig, et al.. (2023). Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. International Journal of Molecular Sciences. 24(1). 818–818. 4 indexed citations

Suppan, Christoph & Marija Balić. (2022). Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer. Breast Care. 18(1). 69–75. 6 indexed citations

10.

Balić, Marija, Kerstin Wimmer, Christoph Suppan, Tajana Silovski, & Christine Brunner. (2022). Expert Discussion: ASCO 2022. Breast Care. 17(4). 430–436. 2 indexed citations

11.

Rinnerthaler, Gabriel, Christian F. Singer, Edgar Petru, et al.. (2022). Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update. Wiener klinische Wochenschrift. 134(19-20). 683–692. 1 indexed citations

12.

Suppan, Christoph. (2022). ESMO 2021—my top three abstracts in breast cancer. memo - Magazine of European Medical Oncology. 15(2). 111–113.

13.

Suppan, Christoph, Florian Posch, Daniel Steiner, et al.. (2021). Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. Cancers. 13(10). 2492–2492. 10 indexed citations

14.

Suppan, Christoph, Ricarda Graf, Stephan Jahn, et al.. (2021). Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. British Journal of Cancer. 126(3). 456–463. 23 indexed citations

15.

Suppan, Christoph, Daniel Steiner, Florian Posch, et al.. (2021). Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients. Breast Care. 16(6). 607–613. 2 indexed citations

16.

Suppan, Christoph, et al.. (2020). Biomarkers in Her2- Positive Disease. Breast Care. 15(6). 586–593. 9 indexed citations

17.

Suppan, Christoph, Daniel Steiner, Florian Posch, et al.. (2020). Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.. Journal of Clinical Oncology. 38(15_suppl). e12520–e12520. 1 indexed citations

18.

Gašparović, Ana Čipak, Lidija Milković, Nadia Dandachi, et al.. (2019). Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype. Antioxidants. 8(12). 633–633. 30 indexed citations

19.

Posch, Florian, Christoph Suppan, Robert E. Hammer, et al.. (2019). Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy. Annals of Surgical Oncology. 26(13). 4274–4283. 31 indexed citations

20.

Suppan, Christoph & Marija Balić. (2017). Early stage breast cancer treatment and prognostic factors. memo - Magazine of European Medical Oncology. 10(2). 82–85. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact